{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":25,"n_cols":5,"rows_kept":25,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[5,2,5,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[11,2,11,3],[12,2,12,3],[13,2,13,3],[15,2,15,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9911034867203321"]
[null,null,"Autore",null,"Sharon Madhuri"]
[null,null,"Titolo",null,"Risk, Safety, and Ethical Concerns in Nanotechnology"]
[null,null,"Pubbl/distr/stampa",null,"Newark : , : John Wiley & Sons, Incorporated, , 2026"]
[{"$nulls":4},"©2025"]
[null,null,"ISBN",null,"1-119-64072-5"]
[{"$nulls":4},"1-119-64069-5"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (329 pages)"]
[null,null,"Collana",null,"Advances in Nanotechnology and Applications Series"]
[null,null,"Disciplina",null,"620/.5"]
[null,null,"Soggetti",null,"Nanotechnology - Moral and ethical aspects"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Cover -- Series Page -- Title Page -- Copyright page -- Dedication Page -- Contents -- Foreword -- Preface -- Prologue -- Part I: Nanotechnology and Risks -- Chapter 1 Understanding Nanoparticles and Their Probable Risks -- 1.1 What is Nanotechnology? -- 1.2 Unique Properties of Nanoparticles that Differentiate Them from Their Bulk Counterpart -- 1.2.1 Magnetic Properties -- 1.2.2 Electrical Properties -- 1.2.3 Thermal Properties -- 1.2.4 Mechanical Properties -- 1.2.5 Chemical/Catalytic Properties -- 1.2.6 Optical Property -- 1.3 Fabrication of Nanoparticles -- 1.4 Uses of Nanoparticles in Consumer Products -- 1.5 Potential Risks Due to Harmful Effects of Nanoparticles -- 1.5.1 Risk Due to Interaction of Nanoparticles with Living Organisms -- 1.5.2 Short- and Long-Term Risks -- 1.6 Need for Measurement of Exposure to Nanoparticles -- 1.7 Conclusion -- References -- Chapter 2 Nanotechnology, Nanoparticles, and Living Systems -- 2.1 Introduction -- 2.2 The Need for Nanotechnology in the Present-Day Scenario Cannot be Ignored -- 2.2.1 Increased Demand for Nanomaterial -- 2.2.2 Cheap and Clean Energy -- 2.2.2.1 Batteries -- 2.2.2.2 Fuel Cell -- 2.2.2.3 Wind Energy -- 2.2.2.4 Hydrogen Energy -- 2.2.3 Food Industry -- 2.2.3.1 Food Packaging Applications -- 2.2.3.2 Food Processing Applications -- 2.2.4 Defense Sector -- 2.2.4.1 Nano Armor -- 2.2.4.2 Nano for Faster and Intensive Medical Help -- 2.2.4.3 Nanotechnology-Based Weapons -- 2.2.4.4 Lighter and Faster Aircraft -- 2.2.4.5 Nanotechnology for Vehicles -- 2.2.4.6 Radar-Absorbing Material (RAM) -- 2.2.4.7 Portable Energy/Power -- 2.2.4.8 Nanotechnology for Satellites -- 2.2.4.9 Nanotechnology for Nuclear, "]
[{"$nulls":4},"Chemical, and Biological Warfare -- 2.2.5 Medical/Healthcare -- 2.2.5.1 Application in Drug Delivery -- 2.2.5.2 Nanodiagnostics Application -- 2.2.5.3 Application in Surgery."]
[{"$nulls":4},"2.2.5.4 Application in Medical Robotics -- 2.2.6 Nanotechnology in Agriculture -- 2.2.6.1 Precision Farming -- 2.3 Interdependence and Interaction between Various Living Systems -- 2.3.1 Life-Cycle and Exposure Challenges -- 2.4 Concerns of Nanoparticle Properties Impacting Interaction with Living System -- 2.5 Concluding Remarks -- References -- Chapter 3 Methodologies for Assessing Risks Associated with Human Health and the Environment by Nanotechnology-Based Products -- 3.1 Introduction -- 3.2 Workplace Exposure to Effects of Engineered Nanoparticles -- 3.3 Effects of Engineered Nanoparticles on Animals, Plants and Environment -- 3.4 Traditional Methods of Risk Assessment of Chemicals -- 3.4.1 What is PM 2.5? -- 3.4.2 Parameters and Concerns for Formulating Methods for Risk Assessment -- 3.4.3 Challenges Related to the Traditional Industrial Hygiene Approach -- 3.4.4 Traditional Instruments for Assessing Exposure -- 3.5 Methods for Risk Assessment of Nanoparticle -- 3.5.1 Control Banding to Analyze and Prioritize Risks from Nanomaterials -- 3.5.2 How to Measure and Assess Exposure to Nanoparticles -- 3.5.2.1 Measurement of Airborne or Gaseous Nanoparticles -- 3.5.2.2 Assessment of Nanoparticles in Liquid -- 3.5.3 Methods Used to Assess the Risk Due to Nanoparticles -- 3.6 Are Sufficient Methods Being Used to Assess the Risk from Nanoparticles? -- 3.6.1 Considerations to Assess Risks that Should be Taken into Account -- 3.6.2 Exposure Factors Required to be Specified for Risk Assessment Methodologies -- 3.6.3 How to Improve the Risk Assessment of Nanoparticles? -- 3.7 Conclusion -- References -- Chapter 4 Human Health Risks Due to Inhaled Nanoparticles -- 4.1 Introduction -- 4.1.1 Sources of Nanoparticles -- 4.1.1.1 Natural Sources of Nanoparticles that we Cannot Avoid -- 4.1.1.2 Anthropogenic Sources of NPs that Need Careful Management."]
[{"$nulls":4},"4.2 Inhalation Routes of NPs from Nose and Lungs to Other Organs of Human Body -- 4.2.1 Translocation of NPs to Different Sites of the Body -- 4.3 Cytotoxicological Considerations -- 4.3.1 Cellular Response -- 4.3.1.1 Oxidative Stress -- 4.3.1.2 Inflammation -- 4.3.1.3 Genotoxicity -- 4.3.1.4 Tumorigenicity -- 4.4 Known Hazardous Impact of Inhaled Nanoparticles on Human Health -- 4.4.1 The Respiratory Tract: Portal of Entry for NPs into the Human Body -- 4.4.2 Blood Circulation System: A Trojan Horse for Inhaled Nanoparticles -- 4.4.3 Cardiovascular System Leading to Cardiopulmonary Disease -- 4.4.4 Digestive System: Can it Digest Nanoparticles? -- 4.4.5 Kidneys: Can They Flux Out All NPs -- 4.4.6 Central Nervous System and Brain without an NP Barrier -- 4.4.7 Nanotoxicity against Reproductive System Organs -- 4.4.8 Hormone or Endocrine System Nanotoxicity -- 4.4.9 Cancer: Are Nanoparticles Friends or Foes? -- 4.5 Lung Bioassay Methodologies for Assessing Hazards after Exposures to Nanoscale or Fine Particulates -- 4.6 Strengths and Weaknesses of Risk Assessment -- 4.7 Concluding Remarks -- Bibliography -- Chapter 5 Dermal Entry Route of NPs into the Human Body: A Risk? -- 5.1 Introduction -- 5.2 Dermal Entry Route of Nanoparticles -- 5.2.1 Pathways for Skin Absorption of Nanoparticles -- 5.2.1.1 Stratum Corneum (SC) -- 5.2.1.2 Skin Appendages -- 5.2.1.3 Interaction and Impact of Dermally Absorbed Nanoparticles with Biomolecules -- 5.3 Health Hazards of Dermal Exposure to NPs -- 5.4 Risk Handling and Evaluation of Dermal Exposure Hazards -- 5.5 Conclusion -- References -- Chapter 6 Different Exposure Scenarios and Nanotoxicological Information -- 6.1 "]
[{"$nulls":4},"Introduction -- 6.2 Exposure Scenario to NPs -- 6.3 Nanoparticle Exposure and Biokinetic Pathways -- 6.3.1 Biokinetic Pathway of NPs via Inhalation -- 6.3.2 Biokinetic Pathway of Injected NPs."]
[{"$nulls":4},"6.3.3 Biokinetics Pathway of Dermal Exposure to NPs -- 6.4 Nanotoxicity and Potential Mechanism -- 6.4.1 Size and Size Distribution of NPs -- 6.4.2 Morphology of NPs -- 6.4.3 Surface Properties Such as Surface Area (SA) and Mass Ratio (MR) -- 6.4.4 Chemical Composition and Surface Characteristics of NPs -- 6.4.5 Insolubility or Low Water Solubility of NPs -- 6.4.6 Agglomeration/Aggregation of NPs -- 6.5 Assessment of Toxicity of Nanoparticles -- 6.5.1 In-Vitro Toxicity Assay Method -- 6.5.2 In-Vivo Toxicity Assay Method -- 6.5.2.1 Histopathological Analysis -- 6.5.2.2 Blood Chemistry Analysis -- 6.5.2.3 Immunotoxicity Assessment -- 6.5.2.4 Genotoxicity Testing -- 6.5.2.5 Reproductive and Developmental Toxicity Studies -- 6.5.2.6 Organ-Specific Toxicity Assessment -- 6.5.2.7 Long-Term Exposure Studies -- 6.5.2.8 Behavioral Studies -- 6.5.2.9 Metabolomics and Proteomics -- 6.6 Risk Management of NPS -- 6.6.1 Identification of Hazards Caused by Nanomaterials -- 6.6.2 Guidance on Available Methods for Risk Assessment of Nanomaterials -- 6.6.3 (Q)SAR Models for Regulatory Assessment of Nanomaterial Risks -- 6.6.4 Can AI Help in Risk Management of NPs -- 6.6.4.1 Analyzing Data and Predictive Modeling -- 6.6.4.2 Toxicity Prediction -- 6.6.4.3 Environmental Impact Assessment (EIA) -- 6.6.4.4 Regulatory Compliance -- 6.7 Conclusion -- References -- Chapter 7 Assessment of Risks Due to Nanoparticles in the Ecosystem -- 7.1 Introduction -- 7.1.1 Airborne Nanoparticles -- 7.1.2 Waterborne Nanoparticles -- 7.1.3 Nanoparticles in Soil -- 7.2 What to Consider for Nanoparticle-Related Assessment of Risks to Ecosystem -- 7.2.1 Identify and Characterize Properties of Nanoparticles of Concern -- 7.2.2 Bioavailability, Uptake and Toxicity Assessment -- 7.2.3 Exposure Assessment Fate and Transport of NP -- 7.2.4 Ecological Effects and Risk Characterization."]
[{"$nulls":4},"7.2.5 Uncertainty and Variability -- 7.2.6 Risk Management and Mitigation -- 7.3 Monitoring and Surveillance -- 7.3.1 Monitoring Strategies -- 7.3.1.1 Remote Sensing -- 7.3.1.2 Tracking Technologies -- 7.3.1.3 Challenges and Considerations -- 7.4 Stakeholder Engagement -- 7.4.1 Government Agencies -- 7.4.2 International Organizations -- 7.4.3 Researchers and Scientists -- 7.4.4 Health Professionals -- 7.4.5 Industry -- 7.4.6 Non-Governmental Organizations (NGOs) -- 7.4.7 Consumers -- 7.4.8 Media -- 7.5 Concluding Remarks -- References -- Part II: Ethical Aspects -- Chapter 8 Ethics Governance and Policies: Problems and Concerns -- 8.1 Introduction -- 8.2 How Does Ethics Pertain to Nanotechnology? -- 8.2.1 Ethics and Nanotechnology in the Workplace -- 8.3 Framework for Ethical Analysis of Nanotechnology -- 8.3.1 Considerations for Framework -- 8.3.2 Privacy -- 8.3.3 Security Concerns -- 8.3.4 Environmental Concerns -- 8.4 Governance and Policies Based on Ethics -- 8.4.1 Subjectivity -- 8.4.2 Complexity -- 8.4.3 Enforcement of Policy -- 8.4.4 Evolution of Ethics and Ethical Dilemmas -- 8.5 Problems and Challenges Faced in Addressing Ethical Concerns -- 8.5.1 Complexity -- 8.5.2 Subjectivity -- 8.5.3 Cost and Resource Constraints -- 8.5.4 Changing Landscapes -- 8.5.5 Lack of Awareness, Education and Training -- 8.5.6 Health and Environment-Related Challenges -- 8.5.7 Organizational Ethics -- 8.5.8 Legal and Regulatory Compliance -- 8.6 Concluding Remarks -- References -- Chapter 9 Bioethical Questions: Ethically Assessing Toxicology and Human Health -- 9.1 Introduction -- 9.2 Organizations Involved in Ethically Assessing Health Risks -- 9.2.1 International Organizations -- "]
[{"$nulls":4},"9.2.1.1 World Health Organization (WHO) -- 9.2.1.2 United Nations Office for Disaster Risk Reduction (UNDRR) -- 9.2.1.3 International Risk Governance Council (IRGC)."]
[{"$nulls":4},"9.2.1.4 International Organization for Standardization (ISO)."]
[null,null,null,"Sommario/riassunto","Navigate the complex world of nanotechnology with this essential guide, providing a comprehensive analysis of the ethical, environmental, and health challenges associated with its cutting-edge innovations."]